Bradley I. Reinfeld

Bradley I. Reinfeld

Auto-generated profile, based on publicly available information

Bradley I. Reinfeld

Department of Medicine, Vanderbilt University Medical Center, Nashville, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
BRBradley I. Reinfeld
Bradley I. Reinfeld
MMMatthew Z. Madden
Matthew Z. Madden
MWMelissa M. Wolf
Melissa M. Wolf
ACAnna Chytil
Anna Chytil
JBJackie E. Bader
Jackie E. Bader
WRW. Kimryn Rathmell
W. Kimryn Rathmell

12 June 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JBJackie E. Bader
Jackie E. Bader
MWMelissa M. Wolf
Melissa M. Wolf
GLGian Luca Lupica-Tondo
Gian Luca Lupica-Tondo
MMMatthew Z. Madden
Matthew Z. Madden
BRBradley I. Reinfeld
Bradley I. Reinfeld
JRJeffrey C. Rathmell
Jeffrey C. Rathmell

1 August 2020 in iScience
Verified
Journal Article
Open access
AVAnna E. Vilgelm
Anna E. Vilgelm
KBKensey Bergdorf
Kensey Bergdorf
MWMelissa Wolf
Melissa Wolf
VBVijaya Bharti
Vijaya Bharti
RSRebecca Shattuck-Brandt
Rebecca Shattuck-Brandt
VWVivian Weiss
Vivian Weiss
Patient-derived cancer organoids hold great potential to accurately model and predict therapeutic responses. Efficient organoid isolation methods that minimize post-collection manipulation of tissues would improve adaptability, accuracy, and applicability to both experimental and real-time clinical settings. Here we present a simple and minimally invasive fine-needle aspiration (FNA)-based organoid culture technique using a variety of tumor types including gastrointestinal, thyroid, melanoma, and kidney. This method isolates organoids directly from patients at the bedside or from resected tissues, requiring minimal tissue processing while preserving the histologic growth patterns and infiltrating immune cells. Finally, we illustrate diverse downstream applications of this technique including in vitro high-throughput chemotherapeutic screens, in situ immune cell characterization, and in vivo patient-derived xenografts. Thus, routine clinical FNA-based collection techniques represent an unappreciated substantial source of material that can be exploited to generate tumor organoids from a variety of tumor types for both discovery and clinical applications.

12 November 2021 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SDStephanie O Dudzinski
Stephanie O Dudzinski
JBJackie E Bader
Jackie E Bader
KBKathryn Beckermann
Kathryn Beckermann
KYKirsten L. Young
Kirsten L. Young
RHRachel Hongo
Rachel Hongo
JRJeffrey C. Rathmell
Jeffrey C. Rathmell
Although obesity can promote cancer, it may also increase immunotherapy efficacy in what has been termed the obesity-immunotherapy paradox. Mechanisms of this effect are unclear, although obesity alters key inflammatory cytokines and can promote an inflammatory state that may modify tumor-infiltrating lymphocytes and tumor-associated macrophage populations. To identify mechanisms by which obesity affects antitumor immunity, we examined changes in cell populations and the role of the proinflammatory adipokine leptin in immunotherapy. Single-cell RNAseq demonstrated that obesity decreased tumor-infiltrating lymphocyte frequencies, and flow cytometry confirmed altered macrophage phenotypes with lower expression of inducible NO synthase and MHC class II in tumors of obese animals. When treated with anti-programmed cell death protein 1 (PD-1) Abs, however, obese mice had a greater absolute decrease in tumor burden than lean mice and a repolarization of the macrophages to inflammatory M1-like phenotypes. Mechanistically, leptin is a proinflammatory adipokine that is induced in obesity and may mediate enhanced antitumor immunity in obesity. To directly test the effect of leptin on tumor growth and antitumor immunity, we treated lean mice with leptin and observed tumors over time. Treatment with leptin, acute or chronic, was sufficient to enhance antitumor efficacy similar to anti-PD-1 checkpoint therapy. Further, leptin and anti-PD-1 cotreatment may enhance antitumor effects consistent with an increase in M1-like tumor-associated macrophage frequency compared with non–leptin-treated mice. These data demonstrate that obesity has dual effects in cancer through promotion of tumor growth while simultaneously enhancing antitumor immunity through leptin-mediated macrophage reprogramming.

16 April 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
MRMichael A. Raddatz
Michael A. Raddatz
THTessa M. Huffstater
Tessa M. Huffstater
MBMatthew Bersi
Matthew Bersi
BRBradley I. Reinfeld
Bradley I. Reinfeld
MMMatthew Z. Madden
Matthew Z. Madden
WMW. David Merryman
W. David Merryman
Objective: Macrophages have been described in calcific aortic valve disease, but it is unclear if they promote or counteract calcification. We aimed to determine how macrophages are involved in calcification using the Notch1 +/− model of calcific aortic valve disease. Approach and Results: Macrophages in wild-type and Notch1 +/− murine aortic valves were characterized by flow cytometry. Macrophages in Notch1 +/− aortic valves had increased expression of MHCII (major histocompatibility complex II). We then used bone marrow transplants to test if differences in Notch1 +/− macrophages drive disease. Notch1 +/− mice had increased valve thickness, macrophage infiltration, and proinflammatory macrophage maturation regardless of transplanted bone marrow genotype. In vitro approaches confirm that Notch1 +/− aortic valve cells promote macrophage invasion as quantified by migration index and proinflammatory phenotypes as quantified by Ly6C and CCR2 positivity independent of macrophage genotype. Finally, we found that macrophage interaction with aortic valve cells promotes osteogenic, but not dystrophic, calcification and decreases abundance of the STAT3β isoform. Conclusions: This study reveals that Notch1 +/− aortic valve disease involves increased macrophage recruitment and maturation driven by altered aortic valve cell secretion, and that increased macrophage recruitment promotes osteogenic calcification and alters STAT3 splicing. Further investigation of STAT3 and macrophage-driven inflammation as therapeutic targets in calcific aortic valve disease is warranted.

21 June 2023 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MMMatthew Z. Madden
Matthew Z. Madden
XYXiang Ye
Xiang Ye
CCChanning Chi
Channing Chi
EFEmilie L. Fisher
Emilie L. Fisher
MWMelissa M. Wolf
Melissa M. Wolf
JRJeffrey C. Rathmell
Jeffrey C. Rathmell
Activated T cells undergo metabolic reprogramming to meet anabolic, differentiation, and functional demands. Glutamine supports many processes in activated T cells, and inhibition of glutamine metabolism alters T cell function in autoimmune disease and cancer. Multiple glutamine-targeting molecules are under investigation, yet the precise mechanisms of glutamine-dependent CD8 T cell differentiation remain unclear. We show that distinct strategies of glutamine inhibition by glutaminase-specific inhibition with small molecule CB-839, pan-glutamine inhibition with 6-diazo-5-oxo-l-norleucine (DON), or by glutamine-depleted conditions (No Q) produce distinct metabolic differentiation trajectories in murine CD8 T cells. T cell activation with CB-839 treatment had a milder effect than did DON or No Q treatment. A key difference was that CB-839–treated cells compensated with increased glycolytic metabolism, whereas DON and No Q–treated cells increased oxidative metabolism. However, all glutamine treatment strategies elevated CD8 T cell dependence on glucose metabolism, and No Q treatment caused adaptation toward reduced glutamine dependence. DON treatment reduced histone modifications and numbers of persisting cells in adoptive transfer studies, but those T cells that remained could expand normally upon secondary Ag encounter. In contrast, No Q–treated cells persisted well yet demonstrated decreased secondary expansion. Consistent with reduced persistence, CD8 T cells activated in the presence of DON had reduced ability to control tumor growth and reduced tumor infiltration in adoptive cell therapy. Overall, each approach to inhibit glutamine metabolism confers distinct effects on CD8 T cells and highlights that targeting the same pathway in different ways can elicit opposing metabolic and functional outcomes.